^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) + tunlametinib (HL-085) (MEK inhibitor, MEK1 inhibitor, MEK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study
Published date:
10/16/2023
Excerpt:
At the RP2D, ORR was 60.0% (95%CI: 32.3%, 83.7%) and mPFS was 10.4 months (95% CI: 5.6, NE). 24 pts with metastatic colorectal cancer (mCRC) at all doses, ORR was 25.0% (95%CI: 9.8%, 46.7%), mDoR was 5.5 months (95% CI: 2.9, NE), and mPFS was 6.2 months (95% CI: 4.8, 7.6). Antitumor activity was also seen in papillary thyroid carcinoma and pancreatic ductal adenocarcinoma....Tunlametinib in combination with vemurafenib showed promising antitumor activity and manageable safety profile in pts with BRAF V600-mutated solid tumors.
Trial ID:
